Sumitomo Mitsui Trust Group Inc. reduced its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 3.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,149,399 shares of the company's stock after selling 108,290 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned about 3.10% of Intellia Therapeutics worth $64,720,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC lifted its holdings in shares of Intellia Therapeutics by 9.2% in the first quarter. Allspring Global Investments Holdings LLC now owns 8,894 shares of the company's stock valued at $245,000 after purchasing an additional 750 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Intellia Therapeutics during the first quarter worth $160,000. Swiss National Bank boosted its position in Intellia Therapeutics by 1.3% in the 1st quarter. Swiss National Bank now owns 167,900 shares of the company's stock valued at $4,619,000 after buying an additional 2,200 shares during the last quarter. ProShare Advisors LLC grew its stake in Intellia Therapeutics by 11.9% during the 1st quarter. ProShare Advisors LLC now owns 23,235 shares of the company's stock valued at $639,000 after purchasing an additional 2,466 shares in the last quarter. Finally, SageView Advisory Group LLC acquired a new stake in shares of Intellia Therapeutics during the first quarter worth approximately $532,000. Institutional investors and hedge funds own 88.77% of the company's stock.
Intellia Therapeutics Trading Down 7.6 %
NTLA traded down $1.15 on Friday, reaching $13.97. The company had a trading volume of 3,680,018 shares, compared to its average volume of 1,681,978. The company has a market capitalization of $1.42 billion, a P/E ratio of -2.57 and a beta of 1.81. The company has a fifty day moving average of $18.75 and a 200-day moving average of $22.09. Intellia Therapeutics, Inc. has a one year low of $13.95 and a one year high of $34.87.
Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.37) by $0.03. The company had revenue of $9.10 million during the quarter, compared to the consensus estimate of $8.28 million. During the same quarter last year, the business earned ($1.38) earnings per share. The company's revenue was down 24.1% on a year-over-year basis. Research analysts predict that Intellia Therapeutics, Inc. will post -5.13 EPS for the current year.
Insider Activity
In other news, CAO Michael P. Dube sold 2,012 shares of the firm's stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the sale, the chief accounting officer now directly owns 47,012 shares of the company's stock, valued at $893,698.12. This trade represents a 4.10 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 3.20% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth
A number of equities analysts recently commented on the company. Royal Bank of Canada reiterated an "outperform" rating and issued a $54.00 price target on shares of Intellia Therapeutics in a research note on Thursday, September 19th. Evercore ISI raised shares of Intellia Therapeutics to a "strong-buy" rating in a report on Friday, August 9th. Robert W. Baird lowered their target price on Intellia Therapeutics from $24.00 to $18.00 and set a "neutral" rating for the company in a report on Friday, October 25th. Chardan Capital cut their price target on Intellia Therapeutics from $94.00 to $88.00 and set a "buy" rating on the stock in a report on Thursday, October 24th. Finally, StockNews.com upgraded Intellia Therapeutics to a "sell" rating in a research report on Friday, November 8th. One research analyst has rated the stock with a sell rating, five have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $55.36.
Check Out Our Latest Report on Intellia Therapeutics
About Intellia Therapeutics
(
Free Report)
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
Recommended Stories
Before you consider Intellia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.
While Intellia Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
